Regression of left ventricular hypertrophy: Hoping for a longer life

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 3, 2002, Pages 141-144

  Sharp, Andrew ^a   Mayet, Jamil ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin; Antihypertensive; Hypertrophy; Regression

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 0036756482     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.032     Document Type: Article

References (30)

1. Veterans Administrative Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 90 through 114 mmHg. JAMA 1970;213:1143-52.
2. Veterans Administrative Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967;202:116-22.
3. Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet 1980;1:1261-7.
4. Medical Research Council Working Party. MRC Trial of mild hypertension: principal results. BMJ 1985;291:97-104.
5. Collins R, Peto R (eds). Antihypertensive drug therapy: Effects on Stroke and Coronary Heart Disease. London: Blackwell Scientific Publications, 1994:1156-64.
6. Staessen, JA, Fagard R, Thija L et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
8. MacMahon S, Neal B, Tzouirion et al. for the PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
9. Williams, B. The renin angiotensin system and cardiovascular disease: hope or hype? JRAAS 2000;1:142-6.
10. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs; results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Study. N Engl J Med 1990;322:1561-6.
12. Levy D, Salomen M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.
13. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
14. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-8.
15. Struthers AD. Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. JRAAS 2001;2:211-14.
16. Liebson PR. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens 1990;3:512-17.
17. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
18. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
19. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomised double-blind studies. JAMA 1996;275:1507-13.
20. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1003.
21. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
22. Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996;9:342-60.
23. Sever PS, Dahlöf B, Poulter NR et al. Rationale, design, methods, and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2002; 19:1139-47.
24. Kjeldsen SE, Julius S, Brunner H et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Pressure 2001;10:83-91.
25. Devereux RB, Palmieri V, Sharpe N et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomised enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001;104:1248-54.
26. Estacio RO, Jefers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
27. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
28. Mayet J, Chapman N, Li CK et al. Ethnic differences in the hypertensive heart and the 24 hour blood pressure profile. Hypertension 1998;31:1190-4.
29. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998;31:1635-40.
30. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21.